Evidence map›Paper›PMID 38267673›Full record

ArticleInternational journal of hematology2024

TBI, etoposide, and cyclophosphamide conditioning for intermediate-risk relapsed childhood acute lymphoblastic leukemia.

Hideaki Ueki, Chitose Ogawa, Hiroaki Goto, Masanori Nishi, Junko Yamanaka, Shinji Mochizuki, Takuro Nishikawa, Tadashi Kumamoto, Ritsuo Nishiuchi, Atsushi Kikuta and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 15 institutions in 1 country.

Hideaki UekiDepartment of Pediatric Hematology/Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Chitose OgawaDepartment of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
Hiroaki GotoDivision of Hematology/Oncology, Kanagawa Children's Medical Center, Yokohama, Japan.
Masanori NishiDepartment of Pediatrics, Faculty of Medicine, Saga University, Saga, Japan.
Junko YamanakaDepartment of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan.
Shinji MochizukiDepartment of Pediatrics, National Center for Global Health and Medicine, Tokyo, Japan.
Takuro NishikawaDepartment of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
Tadashi KumamotoDepartment of Pediatric Oncology, National Cancer Center Hospital, Tokyo, Japan.
Ritsuo NishiuchiDepartment of Pediatrics, Kochi Health Sciences Center, Kochi, Japan.
Atsushi KikutaDepartment of Pediatric Oncology, Fukushima Medical University Hospital, Fukushima, Japan.
Shohei YamamotoDepartment of Pediatrics, Tokai University School of Medicine, Isehara, Japan.
Shunji IgarashiDepartment of Pediatric Hematology/Oncology, Japanese Red Cross Narita Hospital, Narita, Japan.
Atsushi SatoDepartment of Hematology/Oncology, Miyagi Children's Hospital, Sendai, Japan.
Toshinori HoriDepartment of Pediatrics, Aichi Medical University School of Medicine, Nagakute, Japan.
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Tomoyuki WatanabeDepartment of Nutritional Science, Faculty of Psychological and Physical Science, Aichi Gakuin University, Nisshin, Japan.
Takao DeguchiDivision of Cancer Immunodiagnostics, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.
Atsushi ManabeDepartment of Pediatrics, Hokkaido University, Sapporo, Japan.
Keizo HoribeClinical Research Center, NHO Nagoya Medical Center, Nagoya, Japan.
Hidemi ToyodaDepartment of Pediatrics, Graduate School of Medicine, Mie University, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan. htoyoda@med.mie-u.ac.jp.ORCID http://orcid.org/0000-0002-4727-6050
Japanese Red Cross Narita Hospital · JPNagoya Medical Center · JPNational Center for Global Health and Medicine · JPAichi Gakuin University · JPAichi Medical University · JPFukushima Medical University Hospital · JPHokkaido University · JPKagoshima University · JPKanagawa Children's Medical Center · JPMie University · JPMiyagi Children's Hospital · JPNational Center For Child Health and Development · JPSaga University · JPTokai University · JPUniversity of Kochi · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn children with intermediate-risk relapsed acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplantation (allo-HSCT) has markedly improved the outcome of patients with an unsatisfactory minimal residual disease (MRD) response. Total body irradiation (TBI), etoposide (ETP), and cyclophosphamide (CY) have been shown to be equivalent to or better than TBI + ETP for conditioning, so we hypothesized that even greater survival could be achieved due to recent advances in HSCT and supportive care. PROCEDURE: We prospectively analyzed the efficacy and safety of allo-HSCT with a unified conditioning regimen of TBI + ETP + CY in children with intermediate-risk relapsed ALL, based on MRD in the bone marrow after induction, from the Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) ALL-R08-II nationwide cohort (UMIN000002025).

resultsTwenty patients with post-induction MRD ≥ 10

conclusionAllo-HSCT based on post-induction MRD with TBI + ETP + CY conditioning was feasible in Japanese children with intermediate-risk relapsed ALL.

Indexed as

Hematopoietic Stem Cell TransplantationPrecursor Cell Lymphoblastic Leukemia-LymphomaChildCyclophosphamideEtoposideHumansRecurrenceRetrospective StudiesTransplantation ConditioningWhole-Body IrradiationCyclophosphamideEtoposideAcute lymphoblastic leukemiaChildhoodCyclophosphamideEtoposideTransplantation

Identifiers

PMID38267673
OpenAlexW4391187880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.